Avalo Therapeutics, Inc. (AVTX): Capital Expenditures
Older than the company's other figures. The latest Capital Expenditures is for the year ended 2022-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.
$95.0K
Year ended 2022-12-31
-28.7%
3-year compound annual growth
+32.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2022-12-31 | $95.0K | -15.9% | 2023-03-29, From 2022-01-01 |
| 2021-12-31 | $113.0K | +79.4% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $63.0K | -76.0% | 2022-03-02, From 2020-01-01 |
| 2019-12-31 | $262.0K | -53.6% | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | $564.4K | n/m | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $23.3K | -33.1% | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | $34.9K | +74.6% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $20.0K | +2.5% | 2018-04-02, From 2015-01-01 |
| 2014-12-31 | $19.5K | -33.4% | 2017-03-14, From 2014-01-01 |
| 2013-12-31 | $29.3K | n/a | 2016-03-23, From 2013-01-01 |